Whether in combination with conventional chemotherapeutic agents, or CDK inhibitors, we propose that the inhibition of IGF2BP1 function represents a promising novel strategy for future neuroblastoma treatment. The gene discussed is IGF2BP1; the disease is neuroblastoma.